NCT07654296
Assessing Suzetrigine for Pain Reduction Following Ureteroscopic Surgery
At risk: Primary completion moved 3 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Recruitment opened Show 4 more changesShow less
- Primary completion pushed from Dec 31, 2026 to Mar 31, 2027
- Study completion pushed from Mar 31, 2027 to May 31, 2027
- Start date changed from estimate of Oct 1, 2026 to Oct 20, 2026
- Site details revised at 2 of 2 sites
- Notable Start date: Aug 1, 2026 to Oct 1, 2026
- Eligibility criteria expanded, about 4 words
- Secondary endpoints: details revised at 2 of 18 entries
- Site details revised at 2 of 2 sites
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Post-discharge opioid consumption (MME)
Timeframe: 1-2 weeks
Secondary (10)
Post-discharge opioid consumption (MME)
Rate of unplanned care encounters
patient reported outcomes: pain score
patient reported outcomes: PROMIS composite score
patient reported outcomes (PROMIS) pain interfere with your day-to-day activities
Show 5 moreShow less
patient reported outcomes (PROMIS) pain interfere with work around the home
patient reported outcomes (PROMIS) pain interfere with your ability to participate in social activities
patient reported outcomes (PROMIS) pain interfere with your household chores
patient reported outcomes (PROMIS) pain interfere with things you usually do for fun
patient reported outcomes (PROMIS) pain interfere with your enjoyment of social activities
Arms and interventions
multimodal analgesia pathway (standard, no suzetrigine)Active comparator
multimodal analgesia pathway without suzetrigine
suzetrigine with multimodal analgesia pathwayExperimental
addition of suzetrigine to multimodal analgesia pathway
Drugs: multimodal analgesia regimen without suzetrigine, Suzetrigine
Sites
2 sites in 1 country